Loading...

Meet the Team

A world-class team of scientists and executives driving LentiStem forward.

Team

Francisco Martín Molina (PhD)
Francisco Martín Molina (PhD)

Main Founder & President of Scientific Advisory Board

Pioneer in gene and cell therapy, Professor at the University of Granada, and Head of the Gene & Cell Therapy group at GENYO. 30+ years advancing safer & more efficient gene transfer systems, for cancer and rare disease treatment. Holds 13 international patents, 80+ high-impact publications cited over 2,100 times. Former researcher at the Institute of Cancer Research (UK) and UCL Windeyer Institute (UK). Dr Martin is Principal Investigator of the Gene and Cell therapy group at GENYO. His activity in the last 25 years has focused on developing new, more efficient and safer gene transfer systems for application in advanced therapies for the treatment of cancer and rare diseases. He worked at the Institute for Cancer Research (ICR) from 1995 to 1997 and later at the Windeyer Institute of Medical Sciences (UCL) from 1997 to 2002 in London (UK), focusing on vector development. Retrovirals for the development of immunotherapy strategies against cancer. In 2002 he established his own Cell and Gene Therapy (CGT) research group as Ramón y Cajal hired at IPB López Neyra (CSIC) and since 2009 at GENYO. He is secretary of the Board of the Spanish Society of Gene and Cell Therapy. He is a member of the academic committee of the Doctoral Program in Biomedicine (University of Granada) and the Master of Immunology at the UGR. Since 2012 Dr. Martin has published more than 70 scientific and technical articles in international journals, including Nature Biotechnology, Journal of Molecular Biology, Trends in Biochemical Science, EMBO journal, Stem Cells, Molecular Therapy, Journal of Virology, Journal of Immunology, Arthritis & Rheumatism, journal of Virology, and others. His articles have been cited more than 1500 times and have an H = 22 index. He has generated 10 patents related to the development of SAFER AND MORE EFFICIENT gene delivery systems for rare disease gene therapy and immunotherapy against Cancer. Currently his interest is focused on the optimization of gene therapy tools for applications in rare diseases and cancer. In particular, he is studying how to improve the tools to be able to generate advanced therapy drugs (ATMPs) based on the genetic modification of hematopoietic stem cells and T cells. Using these technologies, his group is developing new therapeutic strategies (ATMPs) for the treatment of Pompe disease and refractory leukemia type B. Dr. Francisco Martin is the main founder and scientific advisor to LentiStem Biotech.

Carlos M. Molina (MBA)
Carlos M. Molina (MBA)

Chief Executive Officer (CEO)

19+ years leading large-scale international projects. Expertise in strategic execution, resource management and business growth. Founder of multiple companies including Bioceramic, Debla Desarrollo, and CRISPNA Bio. Currently CEO at Facial Team, a global leader in health sector innovations. Carlos Martín Molina is a Civil Engineer from the University of Granada (1995-2001) and a Master in Economics and Business Management (Executive MBA) from the San Telmo International Institute. He has more than 19 years of experience in the Management and Direction of large projects, such as highways, subways, shopping centers, urbanizations or large residential buildings. During these years, he has worked in first-rate international companies, and his main functions have been the Execution and Monitoring of Strategic Plans, Human Resources Management, Planning of Term Objectives, Cost and Sales and Team Management. In 2012, he founded, together with a group of medical friends, Bioceramic 2012, a company dedicated to the manufacture and sales of sportswear. In 2016, he founded Debla Desarrollo e Infraestructuras, S.L. company dedicated to the Engineering, Construction and Consulting of real estate assets. He currently develops his work as Technical Director in this company, managing all areas of the company, from financial, administrative, technical, to human resources or communication and marketing. Within his activity at Debla, he is the Project Manager of the Facial Team, a company in the health sector, a pioneer worldwide for the type of treatments he performs. In 2017 he founded, together with a team of scientists, LentiStem Biotech, S.L. company dedicated to Gene Therapy, of which he is a founding partner and sole administrator.

Laura Rico (PhD)
Laura Rico (PhD)

Co-CEO LentiStem Biotech

R&D Manager and interim CEO of biotech co. 3 business accelerations certificates (SILO-EOI, AcexHealth And., Incibe-Tetuan V.-Google). Founder & CEO of a Sc.-regulatory consultancy in preclinical R&D for Advanced Therapies. 25+ years experience: Sc. Director of the 1st Spanish cell-th. co. (Cellerix), Precl. R&D Head at the sector's leading public initiative (now "Radytta").

Juan Cabrera (PhD)
Juan Cabrera (PhD)

Expert in Medicine and International Business

Pharmacist, entrepreneur, inventor of the first FDA-approved microtechnology injectable drug (Varithena®). International biotech business experience, with a track record of turning science into market-ready products.

Isabel García (MPA, BBA)
Isabel García (MPA, BBA)

Strategy Director

Exec international experience in the biotech & medical sectors, with a focus on Medical innovation-dev., and Business management & public administrations control (Master’s Degree).

Juan Antonio Marchal MD, PhD
Juan Antonio Marchal MD, PhD

Vice Chair, Advisory Board

Medical doctor, Professor of Anatomy & Embryology, co-founder of biotech spin-offs, and expert in pancreatic cancer, regenerative medicine, and 3D bioprinting.

Julia Martínez Martínez
Julia Martínez Martínez

Chief Accounting Officer (CAO)

Tax and accounting expert with over 20 years’ experience managing full-cycle corporate accounting. Extensive experience in financial management for SMEs and large Graduate in business. Tax and accounting advisor with more than 20 years of experience in the entire cycle of general accounting. She has extensive experience in all tax returns that have been filed with the Tax Agency. Presentation of appeals against notifications and claims from the State Tax Agency and the Junta de Andalucía with more than 90% success. Extensive experience in accounting for SMEs and Large companies, presenting all the annual, quarterly or monthly models that these companies have to present to the state and regional tax agency. Co-founder and CAO of LentiStem Biotech.

Ignacio Serrano Martínez
Ignacio Serrano Martínez

Senior researcher

Specialist in vector development and immunotherapy, co-founder of LentiStem and Aridad Therapeutics.

Jon Ruiz
Jon Ruiz

CTO (Technology)

Researcher in CAR-T cells with special focus on CAR-T development from nanobodies and experience in molecular biology.

Iván García
Iván García

Junior Researcher

Advisory Board

Miguel García Toscano (PhD, MBA)
Miguel García Toscano (PhD, MBA)

Gene Therapy Innovator

Specialist in vector development and immunotherapy, co-founder of LentiStem and Aridad Therapeutics.

David Jiménez
David Jiménez

Biotech Investment Partner

Chairman of the Madrid Stock Exchange, Vice-Chair of BME, and Board Member at SIX Group (Swiss Stock Exchange). Extensive finance and governance experience.

Dr. Verónica Ayllón, PhD
Dr. Verónica Ayllón, PhD

Childhood Leukemia Expert

41 high-impact publications, multiple research fellowships, and a global leader in acute megakaryoblastic leukemia research.

Juan José Diaz Mochón (PhD)
Juan José Diaz Mochón (PhD)

Expert in Nanotechnology and International Business

University of Granada, DestiNA Genomics

Pablo Galindo PhD
Pablo Galindo PhD

Co-Founder & Oral Surgery Innovator

Internationally recognized dental surgeon, 180+ JCR publications, multiple patents, and global speaker.

Prof. Houria Boulaiz,  PhD
Prof. Houria Boulaiz, PhD

Gene Therapy Control Systems Specialist

14 patents, award-winning research career, expert in advanced cancer gene therapy.

Vaibah Bhatia (PhD)
Vaibah Bhatia (PhD)

Expert in Biotechnology and International Business

Extensive experience in protein chemistry, gene transfer, and DNA repair, with notable research published in top journals. CEO and founder of Lamark Biotech

 José Aynat
José Aynat

PharmD, MBA

Harvard Senior Executive Fellow 2025

Want to join us?

Check our career opportunities or send us your CV.

Careers
Top